Chinese Biotech Firm Ascletis Leads Series E Round In American Pharma 3-V Biosciences

An affiliate of Hong Kong-listed Chinese biotech company Ascletis Pharma has led a US$18 million series E financing round in San Francisco-based clinical-stage pharmaceutical firm 3-V Biosciences, said Ascletis in a statement released on Monday. Qianhai Ark Investment and 3-V Biosciences’ existing investors New Enterprise Associates and Kleiner Perkins also participated in this round. All investors […]

Chinese Biotech Firm Ascletis Leads Series E Round In American Pharma 3-V Biosciences comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network